Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $132.9 million.

  • Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) rose 6.90% to $132.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.9 million, marking a year-over-year increase of 6.90%. This contributed to the annual value of $121.0 million for FY2024, which is 74.53% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Shares Outstanding (Diluted Average) of $132.9 million as of Q3 2025, which was up 4.64% from $127.0 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) ranged from a high of $132.9 million in Q3 2025 and a low of $47.3 million during Q1 2021.
  • Over the past 3 years, Arcutis Biotherapeutics' median Shares Outstanding (Diluted Average) value was $121.0 million (recorded in 2024), while the average stood at $101.8 million.
  • Data for Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) shows a peak YoY surged of 101.37% (in 2024) over the last 5 years.
  • Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $49.4 million in 2021, then increased by 11.39% to $55.0 million in 2022, then rose by 25.94% to $69.3 million in 2023, then surged by 74.53% to $121.0 million in 2024, then increased by 6.90% to $132.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $132.9 million for Q3 2025, versus $127.0 million for Q2 2025 and $126.0 million for Q1 2025.